AIM OF THE STUDY: This study investigated the efficacy of Marsypianthes chamaedrys Vahl (Lamiaceae) inflorescence and leaf extracts in inhibiting the inflammatory and coagulant actions of Bothrops atrox venom. MATERIALS AND METHODS: Marsypianthes chamaedrys, which is used in Brazil as a folk medicine to treat snakebites and local inflammatory reactions, was tested in vitro to determine its ability to block indirect phospholipase A(2) and direct coagulant activities and in vivo to determine its ability to inhibit leukocyte migration and cytokine release. RESULTS: In vitro, Marsypianthes chamaedrys showed antiphospholipase A(2) and anticoagulant activities; the latter activity was also confirmed by prothrombin time (PT) and activated partial thromboplastin time (aPTT) in the absence of venom. Of the extracts used, those obtained from the crushed plant had the greater inhibitory activity in in vitro tests, showing that biological activity is affected by the way extracts are obtained. In vivo, Marsypianthes chamaedrys inhibited leukocyte migration and the release of the proinflammatory cytokines IL-6 and TNF-α without altering the concentration of the anti-inflammatory cytokine IL-10. CONCLUSIONS: As specific antivenoms are not effective in neutralizing the local action of Bothrops venoms, characterization of the anti-inflammatory mechanisms induced by Marsypianthes chamaedrys is of vital importance if the extracts of this plant species are to be used in future as adjuvants in the treatment of snakebites.
AIM OF THE STUDY: This study investigated the efficacy of Marsypianthes chamaedrys Vahl (Lamiaceae) inflorescence and leaf extracts in inhibiting the inflammatory and coagulant actions of Bothrops atrox venom. MATERIALS AND METHODS:Marsypianthes chamaedrys, which is used in Brazil as a folk medicine to treat snakebites and local inflammatory reactions, was tested in vitro to determine its ability to block indirect phospholipase A(2) and direct coagulant activities and in vivo to determine its ability to inhibit leukocyte migration and cytokine release. RESULTS: In vitro, Marsypianthes chamaedrys showed antiphospholipase A(2) and anticoagulant activities; the latter activity was also confirmed by prothrombin time (PT) and activated partial thromboplastin time (aPTT) in the absence of venom. Of the extracts used, those obtained from the crushed plant had the greater inhibitory activity in in vitro tests, showing that biological activity is affected by the way extracts are obtained. In vivo, Marsypianthes chamaedrys inhibited leukocyte migration and the release of the proinflammatory cytokines IL-6 and TNF-α without altering the concentration of the anti-inflammatory cytokine IL-10. CONCLUSIONS: As specific antivenoms are not effective in neutralizing the local action of Bothrops venoms, characterization of the anti-inflammatory mechanisms induced by Marsypianthes chamaedrys is of vital importance if the extracts of this plant species are to be used in future as adjuvants in the treatment of snakebites.
Authors: Natália Tribuiani; Alexandro Mateus da Silva; Miriéle Cristina Ferraz; Magali Glauzer Silva; Ana Paula Guerreiro Bentes; Talita Signoreti Graziano; Marcio Galdino dos Santos; José Carlos Cogo; Eliana Aparecida Varanda; Francisco Carlos Groppo; Karina Cogo; Yoko Oshima-Franco Journal: BMC Complement Altern Med Date: 2014-02-08 Impact factor: 3.659
Authors: Wuelton Marcelo Monteiro; Jorge Carlos Contreras-Bernal; Pedro Ferreira Bisneto; Jacqueline Sachett; Iran Mendonça da Silva; Marcus Lacerda; Allyson Guimarães da Costa; Fernando Val; Lisele Brasileiro; Marco Aurélio Sartim; Sâmella Silva-de-Oliveira; Paulo Sérgio Bernarde; Igor L Kaefer; Felipe Gobbi Grazziotin; Fan Hui Wen; Ana Maria Moura-da-Silva Journal: Toxicon X Date: 2020-04-23
Authors: Manoela Torres-Rêgo; Allanny Alves Furtado; Mariana Angélica Oliveira Bitencourt; Maira Conceição Jerônimo de Souza Lima; Rafael Caetano Lisbôa Castro de Andrade; Eduardo Pereira de Azevedo; Thaciane da Cunha Soares; José Carlos Tomaz; Norberto Peporine Lopes; Arnóbio Antônio da Silva-Júnior; Silvana Maria Zucolotto; Matheus de Freitas Fernandes-Pedrosa Journal: BMC Complement Altern Med Date: 2016-08-05 Impact factor: 3.659